Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts"

Circulation. 2013 Sep 10;128(11):e172-3. doi: 10.1161/CIRCULATIONAHA.113.004013.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Atrial Fibrillation / drug therapy*
  • Embolism / prevention & control*
  • Factor Xa / adverse effects*
  • Female
  • Humans
  • Male
  • Morpholines / administration & dosage*
  • Stroke / prevention & control*
  • Thiophenes / administration & dosage*
  • Vitamin K / antagonists & inhibitors*

Substances

  • Morpholines
  • Thiophenes
  • Vitamin K
  • Factor Xa